Contemporary Issues in Lung Cancer: A Nursing PerspectiveMarilyn Haas Jones and Bartlett Publishers, 2003 - 322 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. Contemporary Issues in Lung Cancer addresses all aspects of the disease from incidence, risk factors, and the biology of lung cancer, to the latest modes of treatment. Also discussed are controversies in the detection and screening of lung cancer, and the special issues facing individuals with lung cancer. |
From inside the book
Results 1-3 of 90
Page 50
... treatment of both NSCLC and SCLC . In NSCLC , first - line treatment of advanced disease and combined modality treat- ment of locally advanced disease will be reviewed . Additionally , several clinical questions will be addressed ...
... treatment of both NSCLC and SCLC . In NSCLC , first - line treatment of advanced disease and combined modality treat- ment of locally advanced disease will be reviewed . Additionally , several clinical questions will be addressed ...
Page 112
... treatment is a major event that causes and worsens fatigue . Fatigue related to cancer treatment can have such a negative impact that it almost eludes articulation . Fatigue research that has focused on the impact of treatment ...
... treatment is a major event that causes and worsens fatigue . Fatigue related to cancer treatment can have such a negative impact that it almost eludes articulation . Fatigue research that has focused on the impact of treatment ...
Page 248
... treatment for the patch . Treatment is initiated on the quit day with a dose of 15 or 21 mg . Heavier smokers usually receive treatment with 21 mg whereas those who are light to moderate smokers receive treatment with the lower dose of ...
... treatment for the patch . Treatment is initiated on the quit day with a dose of 15 or 21 mg . Heavier smokers usually receive treatment with 21 mg whereas those who are light to moderate smokers receive treatment with the lower dose of ...
Contents
SEPARATING OUT THE DIFFERENCES BETWEEN LUNG | 3 |
BIOLOGY OF LUNG CANCER | 11 |
CHALLENGES OF CONDUCTING RESEARCH IN WOMEN WITH | 19 |
Copyright | |
20 other sections not shown
Other editions - View all
Common terms and phrases
abstr advanced non-small cell agents assessment associated behavior carboplatin cell carcinoma cell lung cancer chemotherapy chest cisplatin Clinical Oncology clinical trials combination decreased depression diagnosis disease docetaxel dose drug dyspnea etoposide evaluated factors fatigue gemcitabine healthcare impact improve increased individuals with lung intervention irinotecan Journal of Clinical lung cancer patients mediastinoscopy metastasis mg/m² multidisciplinary National Cancer Institute nicotine non-small cell lung Nursing Forum nutritional Oncol Oncology Nursing Oncology Nursing Forum paclitaxel pain palliative palliative care patients with advanced patients with lung Phase II study Phase II trial physical physician postoperative potential pulmonary radiation therapy radiotherapy radon measurements regimens resection response rates risk role SCLC Seminars in Oncology side effects sleep small cell lung smoking cessation Society of Clinical stage support groups surgery surgical symptom management Table thoracic thoracotomy tion tobacco topotecan treatment tumor vinorelbine weight loss